---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-002608"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2022-01-31T23:59:59+00:00"
generated_at: "2026-06-27T13:23:53.293242+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Interpace terminates rights offering due to adverse CMS policy change for thyroid tests

## Summary
- Terminated rights offering and standby purchase agreement with 3K Limited Partnership effective January 28, 2022.
- CMS issued new billing policy: no longer reimburses ThyGeNEXT and ThyraMIR tests when billed together for same beneficiary on same date.
- Company evaluating potential financial impact and preparing an appeal; seeking alternative financing sources.
- CEO stated rights offering termination driven by likely adverse impact of CMS policy change.

## SEC filing metadata
- accession: 0001493152-22-002608
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2022-01-31T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315222002608/0001493152-22-002608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315222002608/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-002608
- JSON: https://secwatch.observer/filing/0001493152-22-002608.json
- Plain text: https://secwatch.observer/filing/0001493152-22-002608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.